| 1 |
Efficacy evaluation of optimized CAR-T therapy against refractory epithelial ovarian cancer |
| Others |
Ovarian cancer |
메소텔린 |
Candidate |
CellenGene |
RS-2023-00217215 |
|
| 2 |
Development of a lead compound for anti-cancer drug using immunoactive attenuated Salmonella |
| Others |
Solid Tumor |
FlaB, ClyA |
Lead |
CNCure biotech Inc. |
RS-2022-00167101 |
|
| 3 |
Candidate development of individualized cancer vaccine for the non-Hodgkin Lymphoma |
| Others |
Non-Hodgkin lymphoma |
Non-Hodgkin Lymphoma |
Candidate |
Progeneer |
RS-2022-00166284 |
|
| 4 |
Preclinical study for the development of MRI contrast agent of innovative artificial melanin |
| Others |
Diagnostic |
Liver, Kidney |
Preclinical |
BL Melanis |
RS-2022-00165594 |
|
| 5 |
Development of therapeutic autologous vaccine against acute myeloid leukemia |
| Others |
AML |
αGC-loaded ECNV of AML |
Hit |
Seoul National University |
RS-2022-00165569 |
|
| 6 |
Development of a combination therapy for colorectal cancer using attenuated Salmonella and anti-PD-L1 antibody |
| Others |
Colorectal cancer |
Colorectal cancer (late stage) patients |
Candidate |
CNCure biotech Inc. |
HN22C0637 |
|
| 7 |
Tumor Targeting Liposomal Formulation of Cathepsin B-specific Doxorubicin Prodrug for Drug Resistant Cancer Treatment |
| Others |
Colerectal cancer, Breast cancer, Ovarian cancer, Pancreatic cancer |
Cathepsin B |
Lead |
Korea Institute of Science and Technology (KIST) |
HN21C0349 |
|
| 8 |
GCM-101: Development of cancer-immunotherapy with oncolytic herpes simplex virus (oHSV) in ovarian cancer |
| Others |
Ovary cancer |
EpCAM |
Lead |
GenCellMed |
HN21C0935 |
|
| 9 |
Lead development study on exosomes with anticancer potential armed with FAF1, a multifunctional tumor suppressor and a genuine exosome cargo |
| Others |
Pancreatic cancer, Liver cancer |
FAF1 |
Lead |
ChungNam National University |
HN21C0048 |
|
